Status:
COMPLETED
Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer
Lead Sponsor:
Trans Tasman Radiation Oncology Group
Collaborating Sponsors:
Peter MacCallum Cancer Centre, Australia
Conditions:
Cancer of the Uterine Cervix
Eligibility:
FEMALE
18+ years
Brief Summary
The researchers propose that it may be corpus invasion, rather than tumour volume per se, which is one of the important determinants of ultimate outcome in cervix cancer. The aim of the proposed prosp...
Detailed Description
This will be a prospective, multicentre, prognostic factor, follow-up study. The study is designed to be as simple as possible: newly diagnosed cervical cancer patients will have key prognostic variab...
Eligibility Criteria
Inclusion
- Newly diagnosed, biopsy proven carcinoma of the uterine cervix.
- Squamous cell, adenocarcinoma, adenosquamous or large cell carcinoma histology.
- FIGO Stage Ib -IVa.
- Maximum clinical tumour diameter recorded.
- MRI done within 30 days prior to registration.
- Intention to treat radically
- Treatment not yet started.
- Written informed consent.
- Available for follow-up.
Exclusion
- Lymphoma, small cell carcinoma and melanoma histology.
- Previous hysterectomy
- Pregnancy
Key Trial Info
Start Date :
January 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 15 2014
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT00193934
Start Date
January 1 2006
End Date
May 15 2014
Last Update
July 12 2017
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
2
Liverpool Hospital
Liverpool, New South Wales, Australia, 1871
3
Calvary Mater Newcastle
Newcastle, New South Wales, Australia, 2298
4
Royal North Shore Hospital
Sydney, New South Wales, Australia, 2069